Tag: Phase II Trial

Aquestive AQST-109 Epinephrine Film

Aquestive Receives Positive FDA Response to Epinephrine Sublingual Film Phase 2...

Response confirms approach and supports the characterization of their novel drug platform.
Aquestive's AQST-109

Aquestive’s Sublingual Emergency Epinephrine Compares Favorably to EpiPen® in EPIPHAST II...

The company announced topline results from their EPIPHAST II study.
Baby

Siolta Begins Phase 2 Study in Newborns of Bacteria Consortia ...

STMC-103H has a combination of bacteria that are depleted in the gut microbiota of infants who go on to develop allergic sensitization and allergic diseases in childhood.
Aquestive AQST-109 Epinephrine Film

Aquestive Reports Positive Results from Sublingual Epinephrine Clinical Trial

Phase 2 study continues to show AQST-109 is safe and well tolerated.
OpenBiome Fecal Capsules

Positive Early Results with Fecal Microbiota Therapy for Peanut-Allergic Patients

Encapsulated stool from non-allergic donors alters the immune system and increases tolerance to peanuts.
Revolo Therapeutics

Revolo Biotherapeutics Announces Open Enrollment for Phase 2 Clinical Trial of...

Revolo Biotherapeutics announced it has activated clinical sites and opened enrollment in a Phase 2 clinical trial of its eosinophilic esophagitis therapy.
COUR Pharma Pipeline

COUR Announces First In-Human Dosing in Proof-of-Concept Trial of CNP-201 to...

CNP-201 is a nanoparticle containing peanut protein that aims to eliminate allergic responses.
Harmony Study

Alladapt Enrolling Participants for Clinical Study of OIT Therapy to Treat...

The study is still seeking participants 4-55 years of age.
COVID Vaccine Being Drawn

Michigan Medicine Helps Lead First National Study on How Highly Allergic...

First volunteer expected to receive an injection April 7 in Ann Arbor with results anticipated this summer.
Peanuts

Study: Few People with Peanut Allergy Tolerate Peanut after Stopping OIT

Continuing with a modest dose confers more protection, NIH-funded study finds.